The Challenges Ahead With Monoclonal Antibodies
Open Access
- 1 December 2020
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 324 (21), 2151-2152
- https://doi.org/10.1001/jama.2020.21872
Abstract
This Viewpoint discusses questions about clinical indication, supply, distribution, and cost and coverage that will need to be resolved if monoclonal antibodiesThis publication has 7 references indexed in Scilit:
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial ResultsThe New England Journal of Medicine, 2021
- Remdesivir for the Treatment of Covid-19 — Final ReportThe New England Journal of Medicine, 2020
- Excess Deaths From COVID-19 and Other Causes, March-July 2020JAMA, 2020
- Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial resultsPublished by Cold Spring Harbor Laboratory ,2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19JAMA, 2020
- Missed Opportunities on Emergency Remdesivir UseJAMA, 2020
- Emergency Use Authorization of Remdesivir The Need for a Transparent Distribution ProcessJAMA, 2020